Where would you like to sign in?

Iris Biotechnologies Receives 2014 IAIR Award - Best Company for Leadership in Personalized Medicine in North America

SANTA CLARA, CA--(Marketwired - April 18, 2014) - Iris Biotechnologies Inc. (OTCQB: IRSB) is a winner of the 2014 IAIR AWARDS, which took place in New York on Tuesday, April 15, 2014, at the Yale Club in Manhattan. (www.iairawards.com). Previous winners include Novartis, IBM, Apple, Microsoft, Samsung and Bank of China.

"It is truly an honor to receive the IAIR Award for Best Company for Leadership in Personalized Medicine," said Simon Chin, President, CEO and founder of Iris Biotechnologies. "This has been a big week for Iris. We were just issued US patent 8,693,751, which enables and accelerates the practice of personalized precision medicine. We have also been asked to present at the 2014 BIO International Convention in San Diego." Iris was previously recognized by Frost & Sullivan's North American Technology Innovation Award in Pharmacogenomics.

The IAIR AWARDS event recognized a number of companies from all over the world. Winners were recommended for business excellence by the IAIR readers' votes, including business and financial journalists in 120 countries, followed by the selection of the editorial staff. (http://www.iairawards.com/methodology.php).

"This award begins a new chapter for Iris Biotechnologies. We expect to have more exciting announcements to make between now and the 2014 BIO International Convention, taking place June 23-26 in San Diego, California. The BIO International Convention is the world's largest biotech conference and exhibition, attracting 15,000 professionals from 4,000 unique organizations in 65 countries," said Mr. Chin.

About Iris Biotechnologies Inc.

Iris Biotechnologies Inc. (OTCBB: IRSB) is a life sciences company focused on providing accurate, affordable precision healthcare, which is the future of medicine. Iris offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. In the treatment of cancer, we can achieve precision analysis of chemotherapy effectiveness as well as risk of recurrence. We accomplish this by incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. By analyzing the totality of who a patient is Iris can offer physicians the necessary information to assist their patients in determining the best medical treatment regimen before the treatment even begins. Iris enables personal precision healthcare by matching patient to targeted treatments, and in some cases, including therapies in clinical trials.

The IAIR AWARDS is focused on Global Economy and Sustainability and is one of the world's leading ranking for excellences in various categories such as Green Economy, Private Equity, Asset Management, Alternative Investments, Business Opportunities, Global Corporate Excellences, and Family Businesses. The selection committee is made up of the scientific committee of IAIR® and IAIREVIEW.org along with a team of dedicated legal, economic and financial journalists around the globe in more than 120 countries.

According to Alexa, a subsidiary company of Amazon.com providing commercial web traffic data, IAIR is ranked # 1 for global and local institutional investors and individual investors. IAIR has more unique and qualified visitors than other global legal and financial awards / rankings such as: Financial Times Wealth Monitor, The Wall Street Journal's Financial News, and Reuters Hedgeworld. The IAIR AWARDS is a global roadshow held in the most strategic financial centers such as Hong Kong, Dubai, London, São Paulo, Milan and New York.